contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


newbury-pharmaceuticals-extends-and-increases-loan-agreement-to-sek-30m-convenes-egm

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Newbury Pharmaceuticals är verksamt inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget bedriver sin verksamhet inom den skandinaviska marknaden. Newbury Pharmaceuticals grundades år 2020 och har sitt huvudkontor i Lund.

Newbury Pharmaceuticals

Newbury Pharmaceuticals AB has agreed to extend and increase the existing loan agreement with AB Slädens Pensionsstiftelse nr 3, securing SEK 30 million in total financing through to 30 June...

<div class="mfn-preamble"><p><strong>Newbury Pharmaceuticals AB has agreed to extend and increase the existing loan agreement with AB Slädens Pensionsstiftelse nr 3, securing SEK 30 million in total financing through to 30 June 2027, and will convene an Extraordinary General Meeting to seek shareholder approval of the amendment. </strong></p></div><div class="mfn-body"><p>Newbury has agreed to a 12-month extension and an increase of SEK 15 million to the loan agreement originally announced on the 18th of September 2023. The total outstanding principal under the loan agreement is SEK 30 million following this amendment. The loan terms remain unchanged except for a new maturity date of 30 June 2027, and it carries an interest rate of 11% per annum, payable at the end of each quarter. The loan is intended to be repaid in cash. No financial advisor has been used, and therefore no transaction costs apply.</p><p>The lender, AB Slädens Pensionsstiftelse nr 3, is represented by Johan Orvelin, who is also a member of the Board of Directors of Newbury Pharmaceuticals AB. The transaction has therefore been treated as a related party transaction. The Board of Directors, with Johan Orvelin recused, has unanimously approved the transaction and concluded that it is conducted on arm’s length terms and is in the best interests of the company and its shareholders.</p><p>Separate notice convening the meeting will be published.</p></div><div class="mfn-footer mfn-contacts mfn-e2b1977b3686"><p><strong class="mfn-heading-1">For more information, contact:</strong></p><hr><p>Karl Karlsson, CEO<br><a href="mailto:karl.karlsson@newburypharma.com" rel="noopener">karl.karlsson@newburypharma.com</a><br>Mobile: +46 46 12 11 20</p><p><a href="http://www.newburypharma.com/" rel="noopener">www.newburypharma.com</a></p></div><div class="mfn-footer mfn-about mfn-488d133b85e8"><p><strong class="mfn-heading-1">About Newbury Pharmaceuticals</strong></p><hr><p>Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and an extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.</p><p>Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar"><p><em>This information is information that Newbury Pharmaceuticals is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-03-26 14:00 CET.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a class="mfn-generated mfn-primary" href="https://storage.mfn.se/75d31a71-36fa-43b7-888a-81ba5b748e78/newbury-pharmaceuticals-extends-and-increases-loan-agreement-to-sek-30m-convenes-egm.pdf" rel="noopener">Newbury Pharmaceuticals extends and increases loan agreement to SEK 30m, convenes EGM</a></p></div>

Newbury Pharmaceuticals extends and increases loan agreement to SEK 30m, convenes EGM

Return on capital (ROE, ROI, ROIC, RONIC)

Finansiella nyckeltal: EV/EBIT, EV/EBITA, EV/EBITDA och EV/Sales

Intervjuer i samband med Stockholm Corporate Finance 17:e Kapitalmarknadsdagar Life Science 2026

Finanslingo enkelt förklarat: EBIT, EBITA och EBITDA 

Avkastning på kapital (ROE, ROI, ROIC, RONIC)